Human umbilical cord mesenchymal stem cells as vehicles of CD20-specific TRAIL fusion protein delivery: A double-target therapy against non-Hodgkin's lymphoma

Molecular Pharmaceutics

Volumn 10, Issue 1, 2013, Pages 142-151

  Yan, Cihui ^a,b   Li, Shuangjing ^a   Li, Zhenzhen ^a   Peng, Hongwei ^a   Yuan, Xiangfei ^a   Jiang, Linlin ^a   Zhang, Yanjun ^a   Fan, Dongmei ^a   Hu, Xiao ^a   Yang, Ming ^a   Xiong, Dongsheng ^a  

^a PEKING UNION MEDICAL COLLEGE   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

CD20; lymphoma; mesenchymal stem cells; target therapy; TRAIL

Indexed keywords

ANTINEOPLASTIC AGENT; CD20 ANTIGEN; FIREFLY LUCIFERASE; HYBRID PROTEIN; ISOLEUCINE; SCFVCD20 STRAIL FUSION PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; CANCER INHIBITION; CELL HOMING; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; MESENCHYMAL STEM CELL; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAJI CELL; SIGNAL TRANSDUCTION; TROPISM; TUMOR XENOGRAFT;

ANIMALS; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEK293 CELLS; HUMANS; JURKAT CELLS; LENTIVIRUS; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, NON-HODGKIN; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED NOD; MICE, SCID; RECOMBINANT FUSION PROTEINS; TISSUE THERAPY; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UMBILICAL CORD;

EID: 84872167781     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300261e     Document Type: Article

References (39)

1. Van, M. T.; Hagenbeek, A. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma Neth. J. Med. 2009, 67, 251-259
2. Cragg, M. S.; Glennie, M. J. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents Blood 2004, 103, 2738-2743
3. Stashenko, P.; Nadler, L. M.; Hardy, R.; Schlossman, S. F. Characterization of a human B lymphocyte-specific antigen J. Immunol. 1980, 125, 1678-1685
4. Nadler, L. M.; Korsmeyer, S. J.; Anderson, K. C.; Boyd, A. W.; Slaughenhoupt, B.; Park, E.; Jensen, J.; Coral, F.; Mayer, R. J.; Sallan, S. E. B cell origin of non-T cell acute lymphoblastic leukemia. A model for discrete stages of neoplastic and normal pre-B cell differentiation J. Clin. Invest. 1984, 74, 332-340
5. Wiezorek, J.; Holland, P.; Graves, J. Death receptor agonists as a targeted therapy for cancer Clin. Cancer Res. 2010, 16, 1701-1708
6. Cha, S. S.; Shin, H. C.; Choi, K. Y.; Oh, B. H. Expression, purification and crystallization of recombinant human TRAI Acta Crystallogr. 1999, 55, 1101-1104
7. Ashkenazi, A.; Pai, R. C.; Fong, S.; Leung, S.; Lawrence, D. A.; Marsters, S. A.; Blackie, C.; Chang, L.; McMurtrey, A. E.; Hebert, A.; DeForge, L.; Koumenis, I. L.; Lewis, D.; Harris, L.; Bussiere, J.; Koeppen, H.; Shahrokh, Z.; Schwall, R. H. Safety and antitumor activity of recombinant soluble Apo2 ligand J. Clin. Invest. 1999, 104, 155-162
8. Kim, M. H.; Billiar, T. R.; Seol, D. W. The secretable form of trimeric TRAIL, a potent inducer of apoptosis Biochem. Biophys. Res. Commun. 2004, 321, 930-935
9. Kim, C. Y.; Jeong, M.; Mushiake, H.; Kim, B. M.; Kim, W. B.; Ko, J. P.; Kim, M. H.; Kim, M.; Kim, T. H.; Robbins, P. D.; Billiar, T. R.; Seol, D. W. Cancer gene therapy using a novel secretable trimeric TRAIL Gene Ther. 2006, 13, 330-338
10. Jeong, M.; Kwon, Y. S.; Park, S. H.; Kim, C. Y.; Jeun, S. S.; Song, K. W.; Ko, Y.; Robbins, P. D.; Billiar, T. R.; Kim, B. M.; Seol, D. W. Possible novel therapy for malignant gliomas with secretable trimeric TRAIL PLoS One 2009, 4, e4545
11. R. S. Herbst, M. D.; Ebbinghaus, S.; Gordon, M. S.; O'Dwyer, P.; Lieberman, G.; Ing, J.; Kurzrock, R.; Novotny, W.; Eckhardt, G. A phase I safety and pharmacokinetic (PK) study of recombinant Apo2L/TRAIL, an apoptosis inducing protein in patients with advanced cancer J. Clin. Oncol. 2006, 24, 3013 abstract
12. Takeda, K.; Kojima, Y.; Ikejima, K.; Harada, K.; Yamashina, S.; Okumura, K.; Aoyama, T.; Frese, S.; Ikeda, H.; Haynes, N. M.; Cretney, E.; Yagita, H.; Sueyoshi, N.; Sato, N.; Nakanuma, Y.; Smyth, M. J. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 10895-10900
13. Daniel, D.; Yang, B.; Lawrence, D. A.; Totpal, K.; Balter, I.; Lee, W. P.; Gogineni, A.; Cole, M. J.; Yee, S. F.; Ross, S.; Ashkenazi, A. Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts Blood 2007, 110, 4037-4046
14. Vega, M. I.; Baritaki, S.; Huerta-Yepez, S.; Martinez-Paniagua, M. A.; Bonavida, B. A potential mechanism of rituximab-induced inhibition of tumor growth through its sensitization to tumor necrosis factor-related apoptosis-inducing ligand-expressing host cytotoxic cells Leuk. Lymphoma 2011, 52, 108-121
15. Maddipatla, S.; Hernandez-Ilizaliturri, F. J.; Knight, J.; Czuczman, M. S. Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20 Clin. Cancer Res. 2007, 13, 4556-4564
16. Loebinger, M. R.; Eddaoudi, A.; Davies, D.; Janes, S. M. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer Cancer Res. 2009, 69, 4134-4142
17. Kim, S. M.; Lim, J. Y.; Park, S. I.; Jeong, C. H.; Oh, J. H.; Jeong, M.; Oh, W.; Park, S. H.; Sung, Y. C.; Jeun, S. S. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma Cancer Res. 2008, 68, 9614-9623
18. Grisendi, G.; Bussolari, R.; Cafarelli, L.; Petak, I.; Rasini, V.; Veronesi, E.; De. Santis, G.; Spano, C.; Tagliazzucchi, M.; Barti-Juhasz, H.; Scarabelli, L.; Bambi, F.; Frassoldati, A.; Rossi, G.; Casali, C.; Morandi, U.; Horwitz, E. M.; Paolucci, P.; Conte, P.; Dominici, M. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy Cancer Res. 2010, 70, 3718-3729
19. Choi, S. A.; Hwang, S. K.; Wang, K. C.; Cho, B. K.; Phi, J. H.; Lee, J. Y.; Jung, H. W.; Lee, D. H.; Kim, S. K. Therapeutic efficacy and safety of TRAIL-producing human adipose tissue-derived mesenchymal stem cells against experimental brainstem glioma Neuro-Oncology 2011, 13, 61-69
20. Vilalta, M.; Degano, I. R.; Bago, J.; Gould, D.; Santos, M.; Garcia-Arranz, M.; Ayats, R.; Fuster, C.; Chernajovsky, Y.; Garcia-Olmo, D.; Rubio, N.; Blanco, J. Biodistribution, long-term survival, and safety of human adipose tissue-derived mesenchymal stem cells transplanted in nude mice by high sensitivity non-invasive bioluminescence imaging Stem Cells Dev. 2008, 17, 993-1003
21. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing N. Engl. J. Med. 1986, 315, 1650-1659
22. Gotherstrom, C.; Ringden, O.; Tammik, C.; Zetterberg, E.; Westgren, M.; Le Blanc, K. Immunologic properties of human fetal mesenchymal stem cells Am. J. Obstet. Gynecol. 2004, 190, 239-245
23. Helfrich, W.; Haisma, H. J.; Magdolen, V.; Luther, T.; Bom, V. J.; Westra, J.; V. D. Hoeven, R.; Kroesen, B. J.; Molema, G.; de. Leij, L. A rapid and versatile method for harnessing scFv antibody fragments with various biological effector functions J. Immunol. Methods 2000, 237, 131-145
24. Bremer, E.; Kuijlen, J.; Samplonius, D.; Walczak, H.; de. Leij, L.; Helfrich, W. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2 Int. J. Cancer 2004, 109, 281-290
25. Bremer, E.; Samplonius, D. F.; Peipp, M.; van Genne, L.; Kroesen, B. J.; Fey, G. H.; Gramatzki, M.; de. Leij, L. F.; Helfrich, W. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7 Cancer Res. 2005, 65, 3380-3388
26. Xiong, D. S.; Zheng, M. J.; Liu, Y. X.; Xu, Y. F.; Wang, J. H.; Yang, C. Z. [High level expression of chimeric antibody fragment F(ab')2 directed against CD20 in Escherichia coli] Shengwu Gongcheng Xuebao 2004, 20, 673-678
27. Ma, L.; Feng, X. Y.; Cui, B. L.; Law, F.; Jiang, X. W.; Yang, L. Y.; Xie, Q. D.; Huang, T. H. Human umbilical cord Wharton's Jelly-derived mesenchymal stem cells differentiation into nerve-like cells Chin. Med. J. (Engl.) 2005, 118, 1987-1993
28. Harbury, P. B.; Zhang, T.; Kim, P. S.; Alber, T. A switch between two-, three-, and four-stranded coiled coils in GCN4 leucine zipper mutants Science 1993, 262, 1401-1407
29. Secchiero, P.; Melloni, E.; Corallini, F.; Beltrami, A. P.; Alviano, F.; Milani, D.; D'Aurizio, F.; di Iasio, M. G.; Cesselli, D.; Bagnara, G. P.; Zauli, G. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells Stem Cells 2008, 26, 2955-2963
30. Jo, M.; Kim, T. H.; Seol, D. W.; Esplen, J. E.; Dorko, K.; Billiar, T. R.; Strom, S. C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand Nat. Med. 2000, 6, 564-567
31. Maestroni, G. J.; Hertens, E.; Galli, P. Factor(s) from nonmacrophage bone marrow stromal cells inhibit Lewis lung carcinoma and B16 melanoma growth in mice Cell. Mol. Life Sci. 1999, 55, 663-667
32. Djouad, F.; Bony, C.; Apparailly, F.; Louis-Plence, P.; Jorgensen, C.; Noel, D. Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells Transplantation 2006, 82, 1060-1066
33. Roorda, B. D.; Elst, A.; Boer, T. G.; Kamps, W. A.; de Bont, E. S. Mesenchymal stem cells contribute to tumor cell proliferation by direct cell-cell contact interactions Cancer Invest. 2010, 28, 526-534
34. Fong, C. Y.; Chak, L. L.; Biswas, A.; Tan, J. H.; Gauthaman, K.; Chan, W. K.; Bongso, A. Human Wharton's jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells Stem Cell Rev. 2011, 7, 1-16
35. Gauthaman, K.; Fong, C. Y.; Suganya, C. A.; Subramanian, A.; Biswas, A.; Choolani, M.; Bongso, A. Extra-embryonic human Wharton's jelly stem cells do not induce tumorigenesis, unlike human embryonic stem cells Reprod. Biomed. Online 2012, 24, 235-246
36. Gauthaman, K.; Yee, F. C.; Cheyyatraivendran, S.; Biswas, A.; Choolani, M.; Bongso, A. Human umbilical cord Wharton's jelly stem cell (hWJSC) extracts inhibit cancer cell growth in vitro J. Cell. Biochem. 2012, 113, 2027-2039
37. Subramanian, A.; Shu-Uin, G.; Kae-Siang, N.; Gauthaman, K.; Biswas, A.; Choolani, M.; Bongso, A.; Chui-Yee, F. Human umbilical cord Wharton's jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells J. Cell. Biochem. 2012, 113, 1886-1895
38. Honczarenko, M.; Le, Y.; Swierkowski, M.; Ghiran, I.; Glodek, A. M.; Silberstein, L. E. Human bone marrow stromal cells express a distinct set of biologically functional chemokine receptors Stem Cells 2006, 24, 1030-1041
39. Kosztowski, T.; Zaidi, H. A.; Quinones-Hinojosa, A. Applications of neural and mesenchymal stem cells in the treatment of gliomas Expert Rev. Anticancer Ther. 2009, 9, 597-612